Practical management of myelofibrosis with ruxolitinib

Internal Medicine Journal

Volumn 45, Issue 12, 2015, Pages 1221-1230

  Ho, P J ^a,b   Marlton, P ^f,g   Tam, C ^j   Stevenson, W ^c   Ritchie, D ^k   Bird, R ^f,h   Dunlop, L C ^d,e   Durrant, S ⁱ   Ross, D M ^l  

^a ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c ROYAL NORTH SHORE HOSPITAL   (Australia)

^d LIVERPOOL HOSPITAL   (Australia)

^e UNIVERSITY OF WESTERN SYDNEY   (Australia)

^f PRINCESS ALEXANDRA HOSPITAL   (Australia)

^g UNIVERSITY OF QUEENSLAND   (Australia)

^h GRIFFITH UNIVERSITY   (Australia)

ⁱ ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

^j PETER MACCALLUM CANCER CENTRE   (Australia)

^k ROYAL MELBOURNE HOSPITAL   (Australia)

^l SA Pathology   (Australia)

more..

Author keywords

Myelofibrosis; Ruxolitinib; Side effects; Therapeutics; Treatment outcome

Indexed keywords

JAK1 PROTEIN, HUMAN; JAK2 PROTEIN, HUMAN; JANUS KINASE; JANUS KINASE 1; JANUS KINASE 2; PROTEIN KINASE INHIBITOR; PYRAZOLE DERIVATIVE; RUXOLITINIB;

ANTAGONISTS AND INHIBITORS; AUSTRALIA; AUTOTRANSPLANTATION; DISEASE MANAGEMENT; DOSE RESPONSE; DRUG ADMINISTRATION; ENZYMOLOGY; GENETICS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; MORTALITY; MUTATION; PRIMARY MYELOFIBROSIS; PROCEDURES; PROGNOSIS; QUALITY OF LIFE; REMISSION;

AUSTRALIA; DISEASE MANAGEMENT; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; JANUS KINASE 1; JANUS KINASE 2; JANUS KINASES; MUTATION; PRIMARY MYELOFIBROSIS; PROGNOSIS; PROTEIN KINASE INHIBITORS; PYRAZOLES; QUALITY OF LIFE; REMISSION INDUCTION; TRANSPLANTATION, AUTOLOGOUS;

EID: 84949206545     PISSN: 14440903     EISSN: 14455994     Source Type: Journal    
DOI: 10.1111/imj.12921     Document Type: Article

References (40)

1. Verstovsek S, Kantarjian H, Mesa RA, Pardanani AD, Cortes-Franco J, Thomas DA et al. Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N Engl J Med 2010; 363: 1117-27.
2. Cervantes F. How I treat myelofibrosis. Blood 2014; 124: 2635-42.
3. Patel KP, Newberry KJ, Luthra R, Jabbour E, Pierce S, Cortes J et al. Correlation of mutation profile and response in patients with myelofibrosis treated with ruxolitinib. Blood 2015; 126: 790-7.
4. Mesa RA. Ruxolitinib, a selective JAK1 and JAK2 inhibitor for the treatment of myeloproliferative neoplasms and psoriasis. Idrugs 2010; 13: 394-403.
5. Dupriez B, Morel P, Demory JL, Lai JL, Simon M, Plantier I et al. Prognostic factors in agnogenic myeloid metaplasia: a report on 195 cases with a new scoring system. Blood 1996; 88: 1013-8.
6. Tefferi A, Litzow MR, Pardanani A. Long-term outcome of treatment with ruxolitinib in myelofibrosis. N Engl J Med 2011; 365: 1455-7.
7. Verstovsek S, Kantarjian HM, Estrov Z, Cortes JE, Thomas DA, Kadia T et al. Long-term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls. Blood 2012; 120: 1202-9.
8. Verstovsek S, Mesa RA, Gotlib J, Levy RS, Gupta V, DiPersio JF et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med 2012; 366: 799-807.
9. Verstovsek S, Mesa RA, Gotlib J, Levy RS, Gupta V, DiPersio JF et al. Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow up of COMFORT-I. Haematologica 2015; 100: 479-88.
10. Cervantes F, Dupriez B, Pereira A, Passamonti F, Reilly JT, Morra E et al. New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood 2009; 113: 2895-901.
11. Cervantes F, Vannucchi AM, Kiladjian JJ, Al-Ali HK, Sirulnik A, Stalbovskaya V et al. Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis. Blood 2013; 122: 4047-53.
12. Harrison C, Kiladjian J-J, Al-Ali HK, Gisslinger H, Waltzman R, Stalbovskaya V et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. New England J Med 2012; 366: 787-98.
13. Guglielmelli P, Biamonte F, Rotunno G, Artusi V, Artuso L, Bernardis I et al. Impact of mutational status on outcomes in myelofibrosis patients treated with ruxolitinib in the COMFORT-II study. Blood 2014; 123: 2157-60.
14. Gisslinger H, McMullin MF, Jaekel N, Miller CB, Verstovsek S, Harrison CN et al. A phase Ib, open-label, dose-finding study of ruxolitinib in patients (pts) with primary myelofibrosis (PMF), post-polycythemia vera-myelofibrosis (PPV-MF), or post-essential thrombocythemia-myelofibrosis (PET-MF) and baseline platelets (PLTs) 50 to <100×109/L. 2012 ASCO Annual Meeting 2012.
15. te Boekhorst P, Harrison CN, Gisslinger H, Niederwieser D, Stalbovskaya V, Atienza E et al. A phase 1b, open-label, dose-finding study of ruxolitinib in patients with myelofibrosis (MF) and baseline platelet counts from 50×109/L to 99×109/L (the EXPAND study). Blood 2014; 124: 1841-41.
16. Giraldo P, Palandri F, Palumbo GA, Zaritskey A, Calistri E, Skotnicki A et al. P675 Safety and efficacy of ruxolitinib with intermediate-1-risk myelofibrosis from an open-label, multicenter, single-arm expanded access study. European Hematology Association Vienna 2015.
17. Barosi G, Agarwal M, Zweegman S, Willenbacher W, Pakstyte S, Raymakers R et al. 2844 An individual patient supply program for ruxolitinib for the treatment of patients with primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (PPV-MF), or post-essential thrombocythemia myelofibrosis (PET-MF). 54th ASH Annual Meeting and Exposition. Atlanta, GA; 2012.
18. Mead AJ, Milojkovic D, Knapper S, Garg M, Chacko J, Farquharson M et al. Response to ruxolitinib in patients with intermediate-1-, intermediate-2-, and high-risk myelofibrosis: results of the UK ROBUST Trial. Br J Haematol 2015; 140: 29-39.
19. Scherber R, Dueck AC, Johansson P, Barbui T, Barosi G, Vannucchi AM et al. The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): international prospective validation and reliability trial in 402 patients. Blood 2011; 118: 401-8.
20. Eghtedar A, Verstovsek S, Estrov Z, Burger J, Cortes J, Bivins C et al. Phase 2 study of the JAK kinase inhibitor ruxolitinib in patients with refractory leukemias, including postmyeloproliferative neoplasm acute myeloid leukemia. Blood 2012; 119: 4614-8.
21. Novartis Pharmaceuticals Australia Pty Ltd. Jakavi® (ruxolitinib) product information. 2015.
22. Hamidou Z, Dabakuyo-Yonli TS, Guillemin F, Conroy T, Velten M, Jolly D et al. Impact of response shift on time to deterioration in quality of life scores in breast cancer patients. PLoS One 2014; 9 e96848.
23. Wilkins BS, Radia D, Woodley C, Farhi SE, Keohane C, Harrison CN. Resolution of bone marrow fibrosis in a patient receiving JAK1/JAK2 inhibitor treatment with ruxolitinib. Haematologica 2013; 98: 1872-6.
24. Mesa RA, Komrokji RS, Sun W, Sandor VA, Verstovsek S. Optimizing dose titration of ruxolitinib: the COMFORT-I experience. Blood 2013; 122: 4062-4062.
25. Talpaz M, Paquette R, Afrin L, Hamburg SI, Prchal JT, Jamieson K et al. Interim analysis of safety and efficacy of ruxolitinib in patients with myelofibrosis and low platelet counts. J Hematol Oncol 2013; 6: 81.
26. Bjørn ME, Holmström MO, Hasselbalch HC. Ruxolitinib is manageable in patients with myelofibrosis and severe thrombocytopenia: a report on 12 Danish patients. Leuk Lymphoma 2015. doi:10.3109/10428194.2015.1046867
27. Mesa RA, Gotlib J, Gupta V, Catalano JV, Deininger MW, Shields AL et al. Effect of ruxolitinib therapy on myelofibrosis-related symptoms and other patient-reported outcomes in COMFORT-I: a randomized, double-blind, placebo-controlled trial. J Clin Oncol 2013; 31: 1285-92.
28. Hornakova T, Springuel L, Devreux J, Dusa A, Constantinescu SN, Knoops L et al. Oncogenic JAK1 and JAK2-activating mutations resistant to ATP-competitive inhibitors. Haematologica 2011; 96: 845-53.
29. Dai T, Friedman EW, Barta SK. Ruxolitinib withdrawal syndrome leading to tumor lysis. J Clin Oncol 2013; 31: e430-2.
30. Tefferi A, Pardanani A. Serious adverse events during ruxolitinib treatment discontinuation in patients with myelofibrosis. Mayo Clin Proc 2011; 86: 1188-91.
31. Harrison C, Mesa R, Ross D, Mead A, Keohane C, Gotlib J et al. Practical management of patients with myelofibrosis receiving ruxolitinib. Expert Rev Hematol 2013; 6: 511-23.
32. Stubig T, Alchalby H, Ditschkowski M, Wolf D, Wulf G, Zabelina T et al. JAK inhibition with ruxolitinib as pretreatment for allogeneic stem cell transplantation in primary or post-ET/PV myelofibrosis. Leukemia 2014; 28: 1736-8.
33. Jaekel N, Behre G, Behning A, Wickenhauser C, Lange T, Niederwieser D et al. Allogeneic hematopoietic cell transplantation for myelofibrosis in patients pretreated with the JAK1 and JAK2 inhibitor ruxolitinib. Bone Marrow Transplant 2014; 49: 179-84.
34. Robin M, Francois S, Huynh A, Cassinet B, Bay JO, Boyer F et al. 306 Ruxolitinib before allogeneic hematopoietic stem cell transplantation (HSCT) in patients with myelofibrosis: a preliminary descriptive report of the JAK ALLO Study, a phase II trial sponsored by Goelams-FIM in collaboration with the Sfgmtc. 55th ASH Annual Meeting and Exposition. New Orleans, LA; 2013.
35. Kroger N, Giorgino T, Scott BL, Ditschkowski M, Alchalby H, Cervantes F et al. Impact of allogeneic stem cell transplantation on survival of patients less than 65years of age with primary myelofibrosis. Blood 2015; 125: 3347-50; quiz 64.
36. Hasselbalch HC, Bjorn ME. Ruxolitinib versus standard therapy for the treatment of polycythemia vera. N Engl J Med 2015; 372: 1670-1.
37. Benjamini O, Jain P, Estrov Z, Kantarjian HM, Verstovsek S. Therapeutic effects of ruxolitinib in patients with myelofibrosis without clinically significant splenomegaly. Blood 2012; 120: 2768-9.
38. Heine A, Brossart P, Wolf D. Ruxolitinib is a potent immunosuppressive compound: is it time for anti-infective prophylaxis? Blood 2013; 122: 3843-4.
39. Passamonti F, Cervantes F, Vannucchi AM, Morra E, Rumi E, Pereira A et al. A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment). Blood 2010; 115: 1703-8.
40. National Health and Medical Research Council. NHMRC additional levels of evidence and grades for recommendations for developers of guidelines. Stage 2 Consultation. Early 2008 - end June 2009. Canberra: Commonwealth of Australia; 2009.